Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
CM24 + Nivolumab for Solid Tumors
Recruiting1 awardPhase 1 & 2
Fairfax, Virginia
This trial is testing a new cancer drug (CM-24) in combination with another drug (nivolumab) to see if it is safe and works well against advanced solid tumors, non-small cell lung cancer, and pancreatic cancer.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.